Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for CorMedix (CRMD) over the last 11 years, with Q3 2025 value amounting to $54.7 million.

  • CorMedix's Change in Accured Expenses rose 48449.49% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.5 million, marking a year-over-year increase of 79175.16%. This contributed to the annual value of $23.0 million for FY2024, which is 66741.42% up from last year.
  • CorMedix's Change in Accured Expenses amounted to $54.7 million in Q3 2025, which was up 48449.49% from -$6.6 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Change in Accured Expenses ranged from a high of $54.7 million in Q3 2025 and a low of -$6.6 million during Q2 2025
  • For the 5-year period, CorMedix's Change in Accured Expenses averaged around $4.5 million, with its median value being $457538.0 (2022).
  • Per our database at Business Quant, CorMedix's Change in Accured Expenses surged by 63231.89% in 2021 and then crashed by 72308.62% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Change in Accured Expenses stood at $2.1 million in 2021, then plummeted by 62.39% to $807375.0 in 2022, then plummeted by 209.6% to -$884872.0 in 2023, then surged by 1793.13% to $15.0 million in 2024, then skyrocketed by 265.31% to $54.7 million in 2025.
  • Its Change in Accured Expenses stands at $54.7 million for Q3 2025, versus -$6.6 million for Q2 2025 and $331443.0 for Q1 2025.